Table 2.
SGLT2 inhibitors in clinical development
| Compound | Sponsor | Development phase | Expected approval/launch date |
|---|---|---|---|
| Dapagliflozin | Bristol Myers Squibb, AstraZeneca | 3 | EMA approval given in November 2012; recent NDA resubmission to FDA |
| Canagliflozin | Janssen (Johnson & Johnson), Mitsubishi Tanabe | 3 | FDA approval given in March 2013; EMA decision awaited |
| Empagliflozin | Boehringer Ingelheim, Lilly | 3 | Applications filed with FDA (NDA) and with EMA (MAA) in March 2013 |
| Ipragliflozin | Astellas, Kotobuki | 3 | Marketing approval filed with Japanese regulatory body in March 2013 |
| Luseogliflozin | Taisho | 3 | Marketing approval filed with Japanese regulatory body in April 2013 |
| Tofogliflozin | Chugai, Kowa, Sanofi | 3 | Marketing approval filed with Japanese regulatory body in June 2013 |
| Ertugliflozin (PF04971729) | Pfizer, Merck & Co. | 2 | Not applicable |
| LX4211 | Lexicon Pharmaceuticals | 2 | Not applicable |
| EGT0001442 | Theracos | 2 | Not applicable |
EMA European Medicines Agency, FDA Food and Drug Administration (United States), MAA marketing authorization application, NDA New Drug Application, SGLT2 sodium glucose co-transporter